A Multicenter Double-blind, Randomized, Placebocontrolled Phase I/II Study to Determine the Safety, Tolerability, Potential Efficacy and Dose Finding of INP20, an Oral Formulation for Treatment of Immunotherapy in Peanut-allergic Patients

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 25 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Peanut allergy immunotherapy (Primary)
Indications Peanut hypersensitivity
Focus Adverse reactions
Sponsors InnoUp Farma

Most Recent Events

11 Sep 2024 Planned End Date changed to 1 Dec 2024.
11 Sep 2024 Planned primary completion date changed to 1 Dec 2024.
23 Feb 2024 Results(n=32) assessing safety of INP20 presented at the 2024 Annual Meeting of the American Academy of Allergy, Asthma and Immunology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight